Thanks to early detection and aggressive treatment for prostate cancer, 97 percent of all men diagnosed with the disease will survive at least 5 years and nearly 80 percent will survive at least a ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Details on ...

A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...

Researchers have developed a simple new tool that can identify the risk level of metastatic prostate cancer patients earlier. At the time of diagnosis, the test can predict how well the patient will ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

U.S. Senator John Boozman (R-AR) was recognized for his leadership in advancing policiies that prioritize enhanced care and research for prostate cancer.